Capmatinib-Associated Pseudoacute Kidney Injury in Nonsmall Cell Lung Cancer
Kidney Int Rep
.
2023 Aug 28;8(11):2482-2485.
doi: 10.1016/j.ekir.2023.08.032.
eCollection 2023 Nov.
Authors
Leticia Sandoval
1
2
,
Yeshwanter Radhakrishnan
3
,
Lisa E Vaughan
4
,
Ashley Potter
5
,
Aaron S Mansfield
6
,
Sandra M Herrmann
3
Affiliations
1
Laboratory Medicine and Pathology Mayo Clinic, Rochester, Minnesota, USA.
2
Epigenomics Program, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.
3
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
4
Quantitative Health Sciences Mayo Clinic, Rochester, Minnesota, USA.
5
Department of Pharmacy Mayo Clinic, Rochester, Minnesota, USA.
6
Division of Medical Oncology Mayo Clinic, Rochester, Minnesota, USA.
PMID:
38025245
PMCID:
PMC10658227
DOI:
10.1016/j.ekir.2023.08.032
No abstract available
Keywords:
MET inhibitors; acute kidney injury; cancer therapy; capmatinib; targeted therapy.